Discontinue if signs & symptoms that may be associated w/ cardiac arrhythmia occur. Increased risk of serious ventricular arrhythmias or sudden cardiac death; proarrhythmia. Coadministration w/ potent CYP3A4 inhibitors not shown to cause QT interval prolongation (eg, indinavir); drugs shown to cause QT interval prolongation eg, anti-arrhythmics class IA (eg, disopyramide, quinidine) & III (eg, amiodarone, dofetilide, dronedarone, ibutilide, sotalol), antipsychotics (eg, haloperidol, pimozide, sertindole), antidepressants (eg, citalopram, escitalopram), antibiotics (eg, levofloxacin, moxifloxacin), antifungal agents (eg, pentamidine); antimalarial agents (eg, halofantrine), GI drugs (eg, dolasetron), drugs used in cancer (eg, toremifene, vandetanib), others (eg, bepridil, methadone). Not to be taken simultaneously w/ antacids or antisecretory agents. May be unsuitable for patients w/ sorbitol intolerance. May affect ability to drive & use machines. Severe renal impairment. Contraindicated in moderate (Child-Pugh 7-9) or severe (Child-Pugh >9) hepatic impairment. Pregnancy. Not recommended during lactation. Elderly.